Please wait

.2
Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)THIRD QUARTER
Percent Change
Sales to customers by geographic area20252024TotalOperationsCurrency
U.S.$13,708 12,909 6.2 %6.2 — 
Europe5,440 4,914 10.7 4.4 6.3 
Western Hemisphere excluding U.S.1,231 1,173 4.9 7.3 (2.4)
Asia-Pacific, Africa3,614 3,475 4.0 3.4 0.6 
International10,285 9,562 7.6 4.4 3.2 
Worldwide$23,993 22,471 6.8 %5.4 1.4 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


























Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)NINE MONTHS
Percent Change
Sales to customers by geographic area20252024TotalOperationsCurrency
U.S.$39,557 37,098 6.6 %6.6 — 
Europe15,937 15,291 4.2 1.5 2.7 
Western Hemisphere excluding U.S.3,604 3,579 0.7 7.6 (6.9)
Asia-Pacific, Africa10,531 10,333 1.9 1.8 0.1 
International30,072 29,203 3.0 2.3 0.7 
Worldwide$69,629 66,301 5.0 %4.7 0.3 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.








Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)THIRD QUARTER
Percent Change
Sales to customers by segment of business20252024TotalOperationsCurrency
Innovative Medicine
U.S.$9,402 8,871 6.0 %6.0 — 
International6,161 5,709 7.9 4.3 3.6 
15,563 14,580 6.8 5.3 1.5 
MedTech
U.S.4,306 4,038 6.6 6.6 — 
International4,124 3,853 7.0 4.5 2.5 
8,430 7,891 6.8 5.6 1.2 
U.S.13,708 12,909 6.2 6.2 — 
International10,285 9,562 7.6 4.4 3.2 
Worldwide$23,993 22,471 6.8 %5.4 1.4 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.























Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)NINE MONTHS
Percent Change
Sales to customers by segment of business20252024TotalOperationsCurrency
Innovative Medicine
U.S.$26,655 24,993 6.7 %6.7 — 
International17,983 17,639 1.9 1.3 0.6 
44,638 42,632 4.7 4.5 0.2 
MedTech
U.S.12,902 12,105 6.6 6.6 — 
International12,089 11,564 4.5 3.9 0.6 
24,991 23,669 5.6 5.3 0.3 
U.S.39,557 37,098 6.6 6.6 — 
International30,072 29,203 3.0 2.3 0.7 
Worldwide$69,629 66,301 5.0 %4.7 0.3 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
(Unaudited; in Millions Except Per Share Figures)THIRD QUARTER
20252024Percent
Increase
(Decrease)
AmountPercent
to Sales		AmountPercent
to Sales
Sales to customers$23,993100.0 $22,471100.0 6.8 
Cost of products sold7,30330.4 6,96331.0 4.9 
Gross Profit16,69069.6 15,50869.0 7.6 
Selling, marketing and administrative expenses5,92224.7 5,47824.3 8.1 
Research and development expense3,67215.3 4,95222.0 (25.8)
Interest (income) expense, net180.1 (99)(0.4) 
Other (income) expense, net(478)(2.0)1,7988.0  
Restructuring630.3 410.2 
Earnings before provision for taxes on income7,49331.2 3,33814.9 124.5 
Provision for taxes on income2,3419.7 6442.9 263.5 
Net earnings $5,15221.5 $2,69412.0 91.2 
Net earnings per share (Diluted) $2.12$1.1191.0 
Average shares outstanding (Diluted)2,428.62,427.9
Effective tax rate 31.2%19.3%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$8,43635.2$7,27732.415.9 
Net earnings$6,80128.3$5,87626.115.7 
Net earnings per share (Diluted)$2.80$2.4215.7 
Effective tax rate 19.4%19.3%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
(Unaudited; in Millions Except Per Share Figures)NINE MONTHS
20252024Percent
Increase
(Decrease)
AmountPercent
to Sales		AmountPercent
to Sales
Sales to customers$69,629100.0 $66,301100.0 5.0 
Cost of products sold22,28832.0 20,34330.7 9.6 
Gross Profit47,34168.0 45,95869.3 3.0 
Selling, marketing and administrative expenses16,92324.3 16,41624.8 3.1 
Research and development expense10,41315.0 11,93418.0 (12.7)
In-process research and development impairments—— 1940.3  
Interest (income) expense, net(62)(0.1)(433)(0.7) 
Other (income) expense, net(7,692)(11.1)4,8557.3  
Restructuring1440.2 1920.3  
Earnings before provision for taxes on income27,61539.7 12,80019.3 115.7 
Provision for taxes on income5,9278.6 2,1653.3 173.8 
Net earnings $21,68831.1 $10,63516.0 103.9 
Net earnings per share (Diluted) $8.94$4.38104.1 
Average shares outstanding (Diluted)2,424.82,429.5
Effective tax rate 21.5%16.9%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$24,63535.4$23,55835.54.6 
Net earnings$20,20629.0$19,29629.14.7 
Net earnings per share (Diluted)$8.33$7.944.9
Effective tax rate 18.0%18.1%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.





Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Third Quarter
(Dollars in Millions Except Per Share Data)20252024
Net Earnings, after tax- as reported$5,152 $2,694 
Pre-tax Adjustments
Litigation related15 2,388 
Intangible Asset Amortization expense1,048 1,171 
COVID-19 Vaccine related costs — 4 
Restructuring related 1
168 47 
Medical Device Regulation — 38 
Acquisition, integration and divestiture related 97 328 
(Gains)/losses on securities (387)(37)
Other2 — 
Tax Adjustments
Tax impact on special item adjustments 2
(168)(762)
Tax legislation and other tax related874 5 
Adjusted Net Earnings, after tax$6,801 $5,876 
Average shares outstanding (Diluted)2,428.6 2,427.9 
Adjusted net earnings per share (Diluted)$2.80 $2.42 
Operational adjusted net earnings per share (Diluted)$2.72  
Notes:
1In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.  The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) and $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) primarily includes costs related to market and product exits.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to asset impairments and market and product exits.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Nine Months Ended
(Dollars in Millions Except Per Share Data)20252024
Net Earnings, after tax- as reported$21,688 $10,635 
Pre-tax Adjustments
Litigation related(6,894)5,466 
Intangible Asset Amortization expense3,435 3,355 
COVID-19 Vaccine related costs — 77 
Restructuring related 1
302 207 
Medical Device Regulation — 157 
Acquisition, integration and divestiture related 475 928 
(Gains)/losses on securities (327)374 
IPR&D impairments— 194 
Other29 — 
Tax Adjustments
Tax impact on special item adjustments 2
826 (2,055)
Tax legislation and other tax related672 (42)
Adjusted Net Earnings, after tax$20,206 $19,296 
Average shares outstanding (Diluted)2,424.8 2,429.5 
Adjusted net earnings per share (Diluted)$8.33 $7.94 
Operational adjusted net earnings per share (Diluted)$8.24  
Notes:
1In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.  The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) and $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) primarily includes costs related to market and product exits.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to asset impairments and market and product exits.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.






Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Third quarter 2025 actual vs. 2024 actual
Segments
 Innovative Medicine MedTech  Total
WW As Reported 6.8%6.8%6.8%
U.S. 6.0%6.6%6.2%
International 7.9%7.0%7.6%
WW Currency 1.51.21.4
U.S. ———
International 3.62.53.2
WW Operational 5.3%5.6%5.4%
U.S. 6.0%6.6%6.2%
International4.3 %4.5%4.4%
Caplyta(1.6)(1.1)
U.S.(2.7)(1.9)
International0.00.0
All Other Acquisitions and Divestitures (A&D)0.00.10.1
U.S. 0.00.20.1
International 0.00.10.0
WW Adjusted Operational Ex A&D3.7%5.7%4.4%
U.S.3.3%6.8%4.4%
International4.3 %4.6%4.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Nine months 2025 actual vs. 2024 actual
Segments
 Innovative Medicine MedTech  Total
WW As Reported 4.7%5.6%5.0%
U.S. 6.7%6.6%6.6%
International 1.9%4.5%3.0%
WW Currency 0.20.30.3
U.S. ———
International 0.60.60.7
WW Operational 4.5%5.3%4.7%
U.S. 6.7%6.6%6.6%
International1.3%3.9%2.3%
Shockwave(1.9)(0.6)
U.S.(2.9)(0.9)
International(0.8)(0.2)
Caplyta(1.1)(0.7)
U.S.(1.8)(1.2)
International0.00.0
All Other Acquisitions and Divestitures (A&D)0.00.30.1
U.S. 0.00.40.1
International 0.10.20.1
WW Adjusted Operational Ex A&D3.4%3.7%3.5%
U.S.4.9%4.1%4.6%
International1.4 %3.3%2.2%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.






Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US$3,468 2,816 23.2 %23.2 %—%
Intl3,060 2,565 19.3 14.8 4.5 
WW6,529 5,380 21.3 19.2 2.1 
CARVYKTI
US396 258 53.353.3— 
Intl128 27 ***
WW524 286 83.581.42.1
DARZALEX
US2,088 1,684 24.0 24.0 — 
Intl1,584 1,332 18.9 14.7 4.2 
WW3,672 3,016 21.7 19.9 1.8 
ERLEADA
US378 337 12.3 12.3 — 
Intl558 453 23.0 17.6 5.4 
WW936 790 18.4 15.3 3.1 
IMBRUVICA
US211 259 (18.3)(18.3)— 
Intl483 494 (2.3)(6.6)4.3 
WW695 753 (7.8)(10.6)2.8 
RYBREVANT / LAZCLUZE(3)
US136 68 99.799.7— 
Intl61 21 ***
WW198 89 ***
TALVEY
US85 64 34.2 34.2 — 
Intl37 12 ***
WW122 75 60.8 59.1 1.7 
TECVAYLI
US115 105 9.3 9.3 — 
Intl62 30 ***
WW177 135 31.3 29.9 1.4 
ZYTIGA / abiraterone acetate
US5 5 (25.0)(25.0)— 
Intl108 144 (25.1)(26.8)1.7 
WW113 150 (25.1)(26.8)1.7 
OTHER ONCOLOGY
US56 36 54.6 54.6 — 
Intl39 50 (22.2)(25.6)3.4 
WW94 86 9.7 7.7 2.0 
See footnotes at end of schedule



Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US$2,676 3,068 (12.8)%(12.8)%—%
Intl1,493 1,552 (3.9)(6.3)2.4 
WW4,168 4,621 (9.8)(10.6)0.8 
REMICADE
US326 281 16.2 16.2 — 
US Exports(4)
19 27 (30.9)(30.9)— 
Intl132 112 17.7 16.7 1.0 
WW476 419 13.6 13.3 0.3 
SIMPONI / SIMPONI ARIA
US309 299 3.6 3.6 — 
Intl377 218 73.0 69.8 3.2 
WW687 516 32.9 31.5 1.4 
STELARA
US1,022 1,770 (42.3)(42.3)— 
Intl549 906 (39.4)(41.4)2.0 
WW1,570 2,676 (41.3)(42.0)0.7 
TREMFYA
US989 691 43.1 43.1 — 
Intl434 316 37.4 33.4 4.0 
WW1,424 1,007 41.3 40.1 1.2 
OTHER IMMUNOLOGY
US12 1 **— 
Intl0 0 — — — 
WW12 1 **— 
NEUROSCIENCE
US1,367 1,094 25.0 25.0 — 
Intl658 662 (0.7)(2.6)1.9 
WW2,024 1,755 15.3 14.6 0.7 
CAPLYTA(5)
US240 — **— 
Intl— — — — — 
WW240 — **— 
CONCERTA / methylphenidate
US14 26 (49.2)(49.2)— 
Intl127 117 9.0 8.5 0.5 
WW140 142 (1.4)(1.8)0.4 
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US664 780 (14.9)(14.9)— 
Intl267 269 (0.9)(3.0)2.1 
WW929 1,049 (11.3)(11.9)0.6 
SPRAVATO
US405 243 67.1 67.1 — 
Intl53 42 28.9 23.8 5.1 
WW459 284 61.5 60.8 0.7 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
OTHER NEUROSCIENCE
US$46 46 0.4 %0.4 %—%
Intl210 235 (10.7)(12.3)1.6 
WW256 281 (8.9)(10.2)1.3 
PULMONARY HYPERTENSION
US815 815 (0.1)(0.1)— 
Intl300 287 4.8 2.0 2.8 
WW1,115 1,102 1.1 0.4 0.7 
OPSUMIT / OPSYNVI
US409 417 (1.6)(1.6)— 
Intl168 166 1.1 (1.8)2.9 
WW578 583 (0.8)(1.7)0.9 
UPTRAVI
US392 379 3.5 3.5 — 
Intl92 80 15.2 12.0 3.2 
WW484 458 5.6 5.0 0.6 
OTHER PULMONARY HYPERTENSION
US13 21 (36.5)(36.5)— 
Intl39 39 (1.0)(2.5)1.5 
WW53 60 (13.1)(14.1)1.0 
INFECTIOUS DISEASES
US326 365 (10.5)(10.5)— 
Intl501 471 6.4 0.5 5.9 
WW829 836 (0.9)(4.3)3.4 
EDURANT / rilpivirine
US7 8 (7.9)(7.9)— 
Intl378 323 16.9 9.9 7.0 
WW385 330 16.4 9.5 6.9 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US315 355 (11.0)(11.0)— 
Intl81 94 (13.6)(18.5)4.9 
WW397 449 (11.6)(12.6)1.0 
OTHER INFECTIOUS DISEASES
US4 3 57.3 57.3 — 
Intl42 54 (21.2)(22.3)1.1 
WW47 56 (17.5)(18.5)1.0 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$750 713 5.3%5.3%—%
Intl149 170 (13.1)(15.6)2.5 
WW899 884 1.7 1.2 0.5 
XARELTO
US635 592 7.4 7.4 — 
Intl— — — — — 
WW635 592 7.4 7.4 — 
OTHER
US115 121 (5.2)(5.2)— 
Intl149 170 (13.1)(15.6)2.5 
WW264 292 (9.8)(11.3)1.5 
TOTAL INNOVATIVE MEDICINE
US9,4028,8716.0 6.0 — 
Intl6,1615,7097.9 4.3 3.6 
WW$15,563 14,5806.8%5.3%1.5 %
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US$1,306 1,148 13.8%13.8%—%
Intl908 819 10.8 8.4 2.4 
WW2,213 1,966 12.6 11.6 1.0 
ELECTROPHYSIOLOGY
US720 660 9.1 9.1 — 
Intl698 619 12.6 10.4 2.2 
WW1,418 1,279 10.8 9.7 1.1 
ABIOMED
US336 293 14.5 14.5 — 
Intl86 68 26.8 20.2 6.6 
WW423 362 16.8 15.6 1.2 
SHOCKWAVE(6)
US220 163 34.434.4— 
Intl59 66 (11.2)(12.4)1.2 
WW278 229 21.220.90.3 
OTHER CARDIOVASCULAR
US30 30 0.0 0.0 — 
Intl65 66 (1.0)(2.5)1.5 
WW95 96 (0.7)(1.7)1.0 
ORTHOPAEDICS
US1,396 1,359 2.7 2.7 — 
Intl878 832 5.6 1.9 3.7 
WW2,274 2,191 3.8 2.4 1.4 
HIPS
US262 250 4.7 4.7 — 
Intl144 131 9.7 5.9 3.8 
WW405 381 6.4 5.1 1.3 
KNEES
US216 212 2.1 2.1 — 
Intl160 140 14.3 10.9 3.4 
WW377 352 7.0 5.6 1.4 
TRAUMA
US512 497 3.0 3.0 — 
Intl281 265 6.4 2.5 3.9 
WW793 761 4.2 2.9 1.3 
SPINE, SPORTS & OTHER
US406 400 1.3 1.3 — 
Intl293 296 (1.1)(4.8)3.7 
WW698 696 0.3 (1.3)1.6 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
THIRD QUARTER
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US$1,031 983 4.9 %4.9 %— %
Intl1,511 1,451 4.1 2.2 1.9 
WW2,542 2,434 4.4 3.3 1.1 
ADVANCED
US477 448 6.2 6.2 — 
Intl688 661 4.2 2.1 2.1 
WW1,165 1,109 5.0 3.8 1.2 
GENERAL
US555 535 3.8 3.8 — 
Intl823 791 4.0 2.2 1.8 
WW1,378 1,325 3.9 2.9 1.0 
VISION
US571 549 4.2 4.2 — 
Intl828 751 10.2 7.5 2.7 
WW1,400 1,300 7.7 6.1 1.6 
CONTACT LENSES / OTHER
US456 441 3.5 3.5 — 
Intl562 527 6.6 3.4 3.2 
WW1,018 968 5.2 3.5 1.7 
SURGICAL
US116 108 7.0 7.0 — 
Intl266 225 18.7 17.1 1.6 
WW383 333 14.9 13.8 1.1 
TOTAL MEDTECH
US4,306 4,038 6.6 6.6 — 
Intl4,124 3,853 7.0 4.5 2.5 
WW$8,430 7,891 6.8%5.6%1.2 %
See footnotes at end of schedule







Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US$9,866 7,835 25.9 %25.9 %—%
Intl8,652 7,450 16.1 15.0 1.1 
WW18,519 15,284 21.2 20.6 0.6 
CARVYKTI
US1,072 565 89.689.6— 
Intl260 63 ***
WW1,332 629 ***
DARZALEX
US5,934 4,789 23.9 23.9 — 
Intl4,514 3,797 18.9 17.9 1.0 
WW10,448 8,586 21.7 21.3 0.4 
ERLEADA
US1,048 940 11.5 11.5 — 
Intl1,567 1,275 22.9 21.1 1.8 
WW2,615 2,215 18.0 17.0 1.0 
IMBRUVICA
US685 770 (11.0)(11.0)— 
Intl1,453 1,537 (5.4)(6.4)1.0 
WW2,139 2,307 (7.3)(7.9)0.6 
RYBREVANT / LAZCLUZE(3)
US388 156 **— 
Intl130 49 ***
WW518 205 ***
TALVEY
US235 173 35.8 35.8 — 
Intl79 29 ***
WW314 202 55.3 54.9 0.4 
TECVAYLI
US334 310 7.5 7.5 — 
Intl160 93 73.0 72.6 0.4 
WW494 403 22.6 22.5 0.1 
ZYTIGA / abiraterone acetate
US18 25 (30.4)(30.4)— 
Intl365 470 (22.3)(23.0)0.7 
WW383 496 (22.8)(23.4)0.6 
OTHER ONCOLOGY
US153 106 44.8 44.8 — 
Intl123 136 (9.7)(10.6)0.9 
WW276 242 14.0 13.6 0.4 
See footnotes at end of schedule



Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US$7,377 8,499 (13.2)%(13.2)%—%
Intl4,492 5,090 (11.8)(11.5)(0.3)
WW11,868 13,590 (12.7)(12.6)(0.1)
REMICADE
US923 778 18.7 18.7 — 
US Exports(4)
63 89 (29.6)(29.6)— 
Intl413 380 8.6 10.4 (1.8)
WW1,398 1,246 12.2 12.7 (0.5)
SIMPONI / SIMPONI ARIA
US906 820 10.5 10.5 — 
Intl1,130 787 43.5 44.6 (1.1)
WW2,036 1,607 26.7 27.2 (0.5)
STELARA
US3,081 5,021 (38.6)(38.6)— 
Intl1,768 2,991 (40.9)(40.8)(0.1)
WW4,848 8,012 (39.5)(39.5)0.0 
TREMFYA
US2,384 1,789 33.3 33.3 — 
Intl1,181 932 26.7 26.1 0.6 
WW3,566 2,721 31.0 30.8 0.2 
OTHER IMMUNOLOGY
US21 3 **— 
Intl0 0 — — — 
WW21 3 **—
NEUROSCIENCE
US3,712 3,250 14.2 14.2 — 
Intl2,011 2,090 (3.8)(3.7)(0.1)
WW5,722 5,340 7.2 7.2 0.0 
CAPLYTA(5)
US451 — **— 
Intl— — — — — 
WW451 — **— 
CONCERTA / methylphenidate
US76 101 (24.9)(24.9)— 
Intl376 382 (1.4)(0.4)(1.0)
WW452 482 (6.3)(5.5)(0.8)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US2,021 2,329 (13.2)(13.2)— 
Intl804 830 (3.1)(3.0)(0.1)
WW2,824 3,159 (10.6)(10.5)(0.1)
SPRAVATO
US1,047 660 58.7 58.7 — 
Intl146 120 21.9 21.4 0.5 
WW1,193 780 53.0 52.9 0.1 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
OTHER NEUROSCIENCE
US$119 161 (26.4)%(26.4)%—%
Intl684 759 (9.8)(9.9)0.1 
WW803 920 (12.7)(12.8)0.1 
PULMONARY HYPERTENSION
US2,358 2,324 1.5 1.5 — 
Intl895 866 3.4 2.6 0.8 
WW3,253 3,190 2.0 1.8 0.2 
OPSUMIT / OPSYNVI
US1,175 1,149 2.3 2.3 — 
Intl507 506 0.2 (0.7)0.9 
WW1,682 1,655 1.7 1.4 0.3 
UPTRAVI
US1,139 1,120 1.7 1.7 — 
Intl272 232 17.0 16.4 0.6 
WW1,411 1,352 4.3 4.2 0.1 
OTHER PULMONARY HYPERTENSION
US44 56 (21.5)(21.5)— 
Intl116 127 (8.9)(9.1)0.2 
WW160 183 (12.7)(12.9)0.2 
INFECTIOUS DISEASES
US961 1,023 (6.0)(6.0)— 
Intl1,472 1,599 (7.9)(9.8)1.9 
WW2,434 2,622 (7.2)(8.3)1.1 
EDURANT / rilpivirine
US21 24 (11.8)(11.8)— 
Intl1,082 926 16.8 13.6 3.2 
WW1,103 950 16.1 13.0 3.1 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US932 990 (5.8)(5.8)— 
Intl264 315 (16.1)(16.6)0.5 
WW1,196 1,305 (8.3)(8.4)0.1 
OTHER INFECTIOUS DISEASES
US8 10 (11.0)(11.0)— 
Intl126 358 (64.7)(64.6)(0.1)
WW135 367 (63.3)(63.2)(0.1)
See footnotes at end of schedule
                


Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$2,381 2,061 15.5%15.5%—%
Intl461543(15.2)(14.7)(0.5)
WW2,8422,6059.1 9.2 (0.1)
XARELTO
US1,946 1,697 14.7 14.7 — 
Intl— — — — — 
WW1,946 1,697 14.7 14.7 — 
OTHER
US435 364 19.4 19.4 — 
Intl461 543 (15.2)(14.7)(0.5)
WW896 908 (1.3)(1.0)(0.3)
TOTAL INNOVATIVE MEDICINE
US26,65524,9936.7 6.7 — 
Intl17,98317,6391.9 1.3 0.6 
WW$44,638 42,6324.7%4.5%0.2 %
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US$3,931 3,292 19.4%19.4%—%
Intl2,698 2,353 14.6 13.8 0.8 
WW6,629 5,645 17.4 17.1 0.3 
ELECTROPHYSIOLOGY
US2,145 2,057 4.3 4.3 — 
Intl2,064 1,889 9.2 8.6 0.6 
WW4,209 3,946 6.7 6.4 0.3 
ABIOMED
US1,035 905 14.3 14.3 — 
Intl256 207 23.9 20.7 3.2 
WW1,291 1,112 16.1 15.5 0.6 
SHOCKWAVE(6)
US659 240 **— 
Intl169 66 ***
WW828 306 ***
OTHER CARDIOVASCULAR
US93 89 4.2 4.2 — 
Intl209 192 9.0 8.7 0.3 
WW302 281 7.5 7.2 0.3 
ORTHOPAEDICS
US4,200 4,229 (0.7)(0.7)— 
Intl2,620 2,614 0.3 (1.1)1.4 
WW6,820 6,843 (0.3)(0.8)0.5 
HIPS
US796 785 1.3 1.3 — 
Intl440 435 1.2 0.0 1.2 
WW1,235 1,220 1.3 0.9 0.4 
KNEES
US673 684 (1.5)(1.5)— 
Intl482 463 4.0 3.0 1.0 
WW1,155 1,147 0.7 0.3 0.4 
TRAUMA
US1,515 1,499 1.1 1.1 — 
Intl818 786 4.1 2.7 1.4 
WW2,333 2,285 2.1 1.6 0.5 
SPINE, SPORTS & OTHER
US1,216 1,262 (3.7)(3.7)— 
Intl881 930 (5.3)(6.8)1.5 
WW2,096 2,191 (4.3)(5.0)0.7 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
NINE MONTHS
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US$3,076 2,965 3.8 %3.8 %— %
Intl4,417 4,373 1.0 0.9 0.1 
WW7,493 7,338 2.1 2.1 0.0 
ADVANCED
US1,411 1,360 3.7 3.7 — 
Intl1,991 1,977 0.7 0.5 0.2 
WW3,402 3,337 1.9 1.8 0.1 
GENERAL
US1,666 1,605 3.8 3.8 — 
Intl2,426 2,397 1.2 1.3 (0.1)
WW4,092 4,001 2.3 2.3 0.0 
VISION
US1,694 1,619 4.7 4.7 — 
Intl2,354 2,224 5.8 5.0 0.8 
WW4,048 3,843 5.3 4.8 0.5 
CONTACT LENSES / OTHER
US1,337 1,288 3.8 3.8 — 
Intl1,565 1,508 3.8 2.4 1.4 
WW2,902 2,796 3.8 3.1 0.7 
SURGICAL
US358 331 8.0 8.0 — 
Intl789 717 10.1 10.3 (0.2)
WW1,147 1,048 9.4 9.6 (0.2)
TOTAL MEDTECH
US12,902 12,105 6.6 6.6 — 
Intl12,089 11,564 4.5 3.9 0.6 
WW$24,991 23,669 5.6%5.3%0.3 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
*    Percentage greater than 100% or not meaningful
(1)Operational growth excludes the effect of translational currency
(2)Unaudited
(3)Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4)Reported as U.S. sales
(5)Acquired with Intra-Cellular Therapies on April 2, 2025
(6)Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes ~$20M of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting.